Fabomotizole corrects behavioral impairments in a postnatal propionic acid model of autism spectrum disorders in rats
Open Access
- 22 July 2026
- journal article
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 59-66
Abstract
Background. Postnatal administration of propionic acid (PPA) to rats during the period of active neural network maturation models persistent behavioral disorders characteristic of autism spectrum disorders (ASD). Fabomotizole, which has a multifactorial mechanism of action (sigma-1 receptor activation, modulation of GABAergic and glutamatergic transmission), may have a corrective effect on these disorders. Objective. To study the effect of fabomotizole on behavioral disorders in Wistar rats with an ASD model induced by postnatal PPA administration. Methods. ASD was modeled in male Wistar rats by subcutaneous injections of PPA at a dose of 500 mg/kg on postnatal days 21–25 (P21–P25). Fabomotizole (10 mg/kg) was administered orally daily from P26 until the end of the experiment. Between P52 and P85, social behavior (Pair Test), stereotypy (Autogrooming), anxiety (Open Field Test, Elevated Plus Maze), exploratory activity (Hole Board Test), cognitive functions (Y-maze), and response to aversive odor were assessed. Results. Postnatal PPA administration caused persistent impairments: social deficit (4.3-fold decrease in communicative acts, 26-fold increase in aggression), stereotypy (6.4-fold increase in grooming duration), anxiety (4.4-fold decrease in time spent in open arms), cognitive deficit (2.2-fold decrease in Y-maze patrolling efficiency), and disrupted species-specific behavior. Fabomotizole corrected the PPA-induced impairments: normalized social behavior (4.6-fold increase in communicative acts, 10.5-fold decrease in aggression), reduced stereotypy (5.5-fold decrease in grooming duration), exerted an anxiolytic effect (8.5-fold increase in time spent in open arms), and improved cognitive functions (2.7-fold increase in patrolling efficiency). Conclusion. Fabomotizole at a dose of 10 mg/kg with long-term oral administration attenuates the main behavioral disorders in rats with the postnatal PPAinduced ASD model, confirming its therapeutic potential against persistent symptoms of autism spectrum disorder.Keywords
This publication has 19 references indexed in Scilit:
- Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1/M2 microglia polarizationProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2024
- Biomarkers of mitochondrial dysfunction in autism spectrum disorder: A systematic review and meta-analysisNeurobiology of Disease, 2024
- Modafinil Improves Autism-like Behavior in Rats by Reducing NeuroinflammationJournal of Neuroimmune Pharmacology, 2023
- PlexinA1 deficiency in BALB/cAJ mice leads to excessive self-grooming and reduced prepulse inhibitionIBRO Reports, 2020
- Propionic acid induced behavioural effects of relevance to autism spectrum disorder evaluated in the hole board test with ratsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2020
- Systemic treatment with the enteric bacterial metabolic product propionic acid results in reduction of social behavior in juvenile rats: Contribution to a rodent model of autism spectrum disorderDevelopmental Psychobiology, 2019
- Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across speciesProgress in Neurobiology, 2013
- Comparison between low doses of TMT and cat odor exposure in anxiety- and fear-related behaviors in miceBehavioural Brain Research, 2013
- Afobazole Modulates Microglial Function via Activation of Both σ-1 and σ-2 ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The neurobiological basis of spontaneous alternationNeuroscience & Biobehavioral Reviews, 2002